This study is for men with prostate cancer (prostate adenocarcinoma) who are considering a type of radiation therapy called stereotactic body radiotherapy (SBRT). Researchers want to see if boosting the radiation dose to the entire prostate gland or only to the main tumor (dominant intra-prostatic lesion, DIL) makes a difference in side effects. You would receive SBRT, with one of these two boost methods. The main goal is to compare how often patients experience moderate to severe urinary or digestive side effects between 6 months and 2 years after treatment. This study is currently recruiting and plans to enroll 186 participants.

Study design

This is a phase 2/3 randomized study involving 186 participants. You would be randomly assigned to one of two treatment groups.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 5 years after completing treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.